Tech Company Financing Transactions
iVexSol Funding Round
iVexSol closed a $23.8 million Series A funding round on 1/26/2023. Investors included Asahi Kasei, BioLife Solutions and Bristol-Myers Squibb.
Transaction Overview
Company Name
Announced On
1/26/2023
Transaction Type
Venture Equity
Amount
$23,800,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to invest in its Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
17 Briden St.
Worcester, MA 01605
USA
Worcester, MA 01605
USA
Phone
Undisclosed
Website
Email Address
Overview
iVexSol is a viral vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process that transforms the way these essential gene-delivery vehicles are made. Its technology will greatly reduce the complexity, cost, and development time of these critical reagents, thereby accelerating the development and enabling greater access to life-changing cell.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rod Rietze
Chief Scientific Officer
Michael Greene
Browse more venture capital transactions:
Prev: 1/26/2023: TP24 venture capital transaction
Next: 1/26/2023: Elaborate venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs